BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

855 related articles for article (PubMed ID: 9225643)

  • 1. Selection and performance of the levonorgestrel-releasing intrauterine system.
    Lähteenmäki P; Bardin CW; Elomaa K; Haukkamaa M; Kivijärvi A; Kuukankorpi A; Venhola M; Tuominen J
    Acta Obstet Gynecol Scand Suppl; 1997; 164():69-74. PubMed ID: 9225643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].
    Imperato F; Perniola G; Mossa B; Marziani R; Perniola F; Stragapede B; Napolitano C
    Minerva Ginecol; 2002 Jun; 54(3):271-8. PubMed ID: 12063443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
    Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
    Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development.
    Shaamash AH; Sayed GH; Hussien MM; Shaaban MM
    Contraception; 2005 Nov; 72(5):346-51. PubMed ID: 16246660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
    Wildemeersch D; Janssens D; Andrade A
    Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
    Wildemeersch D; Schacht E
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use.
    Rönnerdag M; Odlind V
    Acta Obstet Gynecol Scand; 1999 Sep; 78(8):716-21. PubMed ID: 10468065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding pattern difference between levonorgestrel intrauterine system and copper intrauterine devices inserted immediately post-abortion: a multicenter, prospective, observational cohort study in Chinese women.
    Chen X; Li Q; Wang X; Chen J; Lv W; Shi B; Wang H; Luo J; Li J
    Curr Med Res Opin; 2018 May; 34(5):873-880. PubMed ID: 29298525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
    Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
    Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system.
    Bahamondes MV; Monteiro I; Castro S; Espejo-Arce X; Bahamondes L
    Hum Reprod; 2010 May; 25(5):1158-64. PubMed ID: 20185512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
    French R; Van Vliet H; Cowan F; Mansour D; Morris S; Hughes D; Robinson A; Proctor T; Summerbell C; Logan S; Helmerhorst F; Guillebaud J
    Cochrane Database Syst Rev; 2004; 2004(3):CD001776. PubMed ID: 15266453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis.
    Kelekci S; Kelekci KH; Yilmaz B
    Contraception; 2012 Nov; 86(5):458-63. PubMed ID: 22832203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonally impregnated intrauterine systems (IUSs), versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
    French R; Cowan F; Mansour D; Morris S; Hughes D; Robinson A; Proctor T; Summerbell C; Logan S; Guillebaud J
    Cochrane Database Syst Rev; 2001; (2):CD001776. PubMed ID: 11406007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
    Modesto W; Bahamondes MV; Bahamondes L
    Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. User satisfaction with a levonorgestrel-releasing intrauterine system (LNG-IUS): data from an international survey.
    Römer T; Linsberger D
    Eur J Contracept Reprod Health Care; 2009 Dec; 14(6):391-8. PubMed ID: 19929641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrauterine devices: an effective alternative to oral hormonal contraception.
    Prescrire Int; 2009 Jun; 18(101):125-30. PubMed ID: 19637436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised trial comparing the levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding.
    Busfield RA; Farquhar CM; Sowter MC; Lethaby A; Sprecher M; Yu Y; Sadler LC; Brown P; Johnson N
    BJOG; 2006 Mar; 113(3):257-63. PubMed ID: 16487195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
    Heinemann K; Reed S; Moehner S; Minh TD
    Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use.
    Modesto W; de Nazaré Silva dos Santos P; Correia VM; Borges L; Bahamondes L
    Eur J Contracept Reprod Health Care; 2015 Feb; 20(1):57-63. PubMed ID: 25160484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.